Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQ: TNXP · Real-Time Price · USD
20.17
-6.50 (-24.37%)
At close: Mar 28, 2025, 4:00 PM
20.04
-0.13 (-0.64%)
After-hours: Mar 28, 2025, 7:59 PM EDT
TNXP Revenue
In the year 2024, Tonix Pharmaceuticals Holding had annual revenue of $10.09M with 29.94% growth. Tonix Pharmaceuticals Holding had revenue of $2.58M in the quarter ending December 31, 2024, a decrease of -31.68%.
Revenue (ttm)
$10.09M
Revenue Growth
+29.94%
P/S Ratio
1.47
Revenue / Employee
$98,000
Employees
103
Market Cap
129.79M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
TNXP News
- 2 days ago - Tonix Pharmaceuticals Announces Presentation at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting - GlobeNewsWire
- 4 days ago - Tonix Pharmaceuticals: Potential To Have 'First' New Fibromyalgia Drug In 15 Years - Seeking Alpha
- 4 days ago - Top 2 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga
- 5 days ago - Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia - GlobeNewsWire
- 9 days ago - As Mpox Cases Spread Around the World, Tonix Pharmaceuticals' Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread - Accesswire
- 10 days ago - Absci Posts Downbeat Results, Joins HealthEquity, Tonix Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
- 11 days ago - Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights - GlobeNewsWire
- 16 days ago - Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring 2025 - GlobeNewsWire